2 unknown, 1 completed. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Completed 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Collaborative Medicinal Development Pty Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001 Cu(II)ATSM - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Collaborative Medicinal Development Pty Limited | 55 | 2020-03-19 | 2022-02-17 |
| CuATSM Compared With Placebo for Treatment of ALS/MND Cu(II)ATSM, Placebos - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Unknown | Collaborative Medicinal Development Pty Limited | 80 | 2019-09-30 | 2019-11-06 |
| ALS Treatment Extension Study Cu(II)ATSM - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Unknown | Collaborative Medicinal Development Pty Limited | 28 | 2018-01-18 | 2022-02-17 |
Amyotrophic Lateral Sclerosis (3)
copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) (3) · Copper (2)
Australia (3)
Dominic Rowe, MD (3)